Evaluating the usefulness of CT-scans in the diagnosis and management of chronic obstructive pulmonary disease (COPD) patients with respiratory symptoms.

Respiratory Exacerbation Symptoms in COPD Undergoing Evaluation – The RESCUE study: Evaluating the usefulness of CT-scans in the diagnosis and management of COPD patients with exacerbations of respiratory symptoms. A randomised, interventional, controlled, non-inferiority study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN39235677

Enrollment

310

Registered

2020-12-10

Start date

2020-01-15

Completion date

Unknown

Last updated

2025-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diagnosis and management of COPD patients with exacerbation of respiratory symptoms Respiratory Chronic obstructive pulmonary disease

Interventions

Patients will be randomized 1:1 and will be allocated in two groups. Patients allocated in group A will have a CT-scan whereas patients allocated in group B will have an x-ray. Patients from group B w

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Diagnosed or suspected COPD 2. Able to give informed consent as documented by signature 3. Age =40 years 4. Smoking history =20 PY 5. Suspicion of exacerbation of respiratory symptoms

Exclusion criteria

Exclusion criteria: 1. Pregnant or lactating women 2. Inability or contraindications to undergo a CT-scan eg. pregnancy 3. Clinically significant concomitant diseases such as organ transplantation 4. Acute coronary syndrome – emergency angiography 5. Inability to follow the procedures of the study, e.g. due to language problems, dementia, etc.

Design outcomes

Primary

Measure	Time frame
1. Length of hospital stay measured in days reviewing the medical records 2. Diagnosis and therapy recorded before radiographic finding, after radiographic finding and at discharge by the treating physician	—

Secondary

Measure	Time frame
1. Symptoms measured using the EXACT score questionnaire at baseline, 7, 14, 21 and 28 days 2. COPD assessment test (CAT score questionnaire) at baseline and 30 (+7) days 3. Modified Medical Research Council (MMRC) dyspnea scale at 28 days 4. Circulating biomarkers of COPD severity and outcome measured using blood sample at 28 days 5. Mortality up to 30 (+7) days measured using patient records 6. DECAF score for acute exacerbation measured through Dyspnoea (Questionnaire), Eosinopenia (blood), Consolidation (radiographic finding), Acidaemia (blood gas analysis) and atrial fibrillation (electrocardiogram) at baseline	—

Measure

Time frame

1. Symptoms measured using the EXACT score questionnaire at baseline, 7, 14, 21 and 28 days 2. COPD assessment test (CAT score questionnaire) at baseline and 30 (+7) days 3. Modified Medical Research Council (MMRC) dyspnea scale at 28 days 4. Circulating biomarkers of COPD severity and outcome measured using blood sample at 28 days 5. Mortality up to 30 (+7) days measured using patient records 6. DECAF score for acute exacerbation measured through Dyspnoea (Questionnaire), Eosinopenia (blood), Consolidation (radiographic finding), Acidaemia (blood gas analysis) and atrial fibrillation (electrocardiogram) at baseline

—

Countries

Germany, Greece, Switzerland

Contacts

Public ContactVivian Suarez Domenech

vivian.suarezdomenech@usb.ch+41 61 328 69 17

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026